Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + vintafolide
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + vintafolide is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and vintafolide (EC145), a folate-targeted vinca alkaloid conjugate. Vintafolide is designed to deliver a cytotoxic agent (desacetylvinblastine hydrazide, DAVLBH) specifically to folate receptor (FR) positive cancer cells. The combination showed improved efficacy compared to either agent alone in FR-positive non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma. The combination was evaluated in the Phase 2b TARGET trial.
- Other names
- vintafolide/docetaxel
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))FOLR1 (FRα)Microtubule
Beyond the preview
Go deeper on docetaxel + vintafolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + vintafolide.